No peptide sold for pattern hair loss has produced a hair count in a randomised trial of androgenetic alopecia. GHK-Cu, the copper-bound three-amino-acid peptide sold as a scalp serum, rests on a two-page 1991 conference abstract in C3H mice authored at ProCyte Corporation, the company that sold the copper peptide hair product, and BPC-157 has no hair data in any species. Oral collagen peptides are a different product entirely: one randomised trial reported thicker hair shafts in women with self-reported thinning, and no trial has counted hairs in diagnosed pattern loss. The two treatments with real hair counts are finasteride, which added 138 hairs per 1-inch scalp circle at two years in 1,553 men, and 5% topical minoxidil, which beat placebo on hair count in 393 men over 48 weeks. Both are FDA approved for pattern hair loss. None of the peptides is approved for hair loss or for anything else.
Peptides commonly discussed for hair loss
Safety: Education, not medical advice, and not a protocol for you. GHK-Cu, BPC-157 and TB-500 are not FDA approved for hair loss or any other use. All three were placed in Category 2 of FDA's interim bulk-substances policy, the category for substances judged to raise significant safety risks, and all three now appear in FDA's nominated-but-withdrawn table after the nominations were pulled, which leaves them off the 503A and 503B bulks lists and therefore outside what a compounding pharmacy can lawfully prepare under section 503A. None has a published safety profile for scalp use. Finasteride is absolutely contraindicated in pregnancy because of birth defect risk, women who are or may become pregnant should not handle crushed or broken tablets, it roughly halves PSA readings, and its labelling carries warnings for sexual dysfunction continuing after discontinuation and for depression and suicidal ideation. Topical minoxidil is toxic to cats, and its safety in pregnancy and breastfeeding is not established. Oral minoxidil requires cardiovascular monitoring under a physician. Patchy, painful, scaling, scarring or sudden hair loss needs a dermatologist instead of a serum, because scarred follicles do not regrow on any protocol. Talk to a clinician before starting or stopping anything.
Where to buy
Where to get peptides for hair loss
GHK-Cu
Compare providers →BPC-157
Buy at Swiss Chems →Save 10% at checkout with code tcwisiiu
Some links are affiliate links — we may earn a fee at no extra cost to you. Most peptides aren't FDA-approved — consult a qualified clinician and check your local laws before purchasing.
No peptide sold for pattern hair loss has produced a hair count in a randomised trial of androgenetic alopecia. Finasteride has, in 1,553 men, and 5% topical minoxidil has, in 393. That gap is the whole story of peptides for hair growth.
A peptide is a short chain of amino acids, the same building blocks proteins are made of, cut down to a few links (if this is your first peptide page, start here). The one people put on their scalp is GHK-Cu, a three-amino-acid peptide bound to a copper atom, sold as a serum or a compounded scalp solution. BPC-157 and TB-500 show up in scalp protocols too, injected or dabbed on, borrowed from the injury-repair literature where their research actually sits (our healing round-up and the injury recovery page cover that ground). None of the three has a published hair count in a person.
What are peptides for hair loss, and which ones do people put on their scalp?
Three compounds account for nearly every peptide hair question we get. GHK-Cu is the copper peptide, applied as a topical solution and sometimes injected into the scalp by clinics as mesotherapy. BPC-157 is a synthetic fragment based on a protein found in stomach juice. TB-500 is a fragment of thymosin beta-4. Oral collagen peptides are a fourth category, a hydrolysed protein powder, covered further down.
Most pattern hair loss is androgenetic alopecia, where dihydrotestosterone (DHT, a potent form of testosterone) shrinks scalp follicles over years until they make only fine colourless hairs. Kaufman and colleagues describe it as "androgen-dependent miniaturization of scalp hair follicles" 1. Nothing in the peptide literature reports any effect of GHK-Cu on DHT in either direction, because nobody has measured it. An untested compound is not a DHT blocker, and that is the first reason the copper peptide cannot substitute for the drugs that are.
Do peptides really work for hair loss? The evidence, option by option
Rank the options by what was measured, in what species, in how many people, and the picture resolves quickly. Finasteride 1 mg daily raised hair counts by 107 hairs at one year and 138 at two years versus placebo, in a 1-inch (5.1 cm²) circle of balding vertex scalp, from a baseline of 876 hairs, across 1,553 men aged 18 to 41 1. Topical 5% minoxidil beat both 2% minoxidil and placebo on non-vellus hair count (the thick pigmented hairs, excluding the fine colourless ones a shrinking follicle makes) over 48 weeks in 393 men aged 18 to 49, with 45% more regrowth than the 2% solution 2. Those are the reference scales.
| Option | Best hair evidence | What was measured | Result | US status |
|---|---|---|---|---|
| Finasteride 1 mg/day, oral | Kaufman 1998, 1,553 men, 2 years | Hair count in a 1-inch scalp circle | +107 hairs at year 1 and +138 at year 2 versus placebo, from a baseline of 876; placebo lost hair | FDA approved for male pattern hair loss, prescription only |
| Minoxidil 5% topical, twice daily | Olsen 2002, 393 men, 48 weeks | Non-vellus hair count in a target area | 5% beat 2% and placebo; 45% more regrowth than 2% at week 48 | FDA approved, over the counter |
| GHK-Cu (copper peptide), topical or injected | Trachy 1991, C3H mice, two-page conference abstract | Follicle stimulation in mouse skin | Follicle stimulation reported; no human hair count has ever been published | Not approved. Serums sold as cosmetics with no efficacy review. Injectable GHK-Cu was FDA Category 2 and now sits in the nominated-but-withdrawn table, so it is on neither bulks list 7 |
| BPC-157 | None, in any species | Nothing; no hair study exists | No evidence to grade, and no dose worth printing for this use | Not approved. Previously FDA Category 2, now in the nominated-but-withdrawn table, so on neither bulks list 7 |
| TB-500 (thymosin beta-4 fragment) | None, in any species | Nothing; no hair study exists | No evidence to grade, and no dose worth printing for this use | Not approved. Previously FDA Category 2 as thymosin beta-4 fragment (LKKTETQ), now in the nominated-but-withdrawn table 7 |
If you already own BPC-157 or TB-500 for a non-hair reason, dosing and half-life for those uses are handled in our BPC-157 dosage guide and the BPC-157 and TB-500 half-life write-up. Neither applies to your scalp.
Where the copper peptide hair claim comes from: a 1991 mouse abstract from the company selling it
Follow the citation chain under "GHK-Cu regrows hair" and it ends in one place. Trachy, Fors, Pickart and Uno, "The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice", Annals of the New York Academy of Sciences, 1991, volume 642, pages 468 to 469 3. It runs two pages, and the subjects were mice. The author affiliation printed on it is ProCyte Corporation of Kirkland, Washington, the company that sold the copper peptide hair product. PubMed carries no abstract for it, only the title and the authors. That document is the primary animal hair citation for the peptide most used on human scalps.
The second pillar is a mechanism review by Pickart and Margolina in the International Journal of Molecular Sciences, 2018, which catalogues GHK's actions on blood vessel outgrowth, collagen and elastin synthesis, fibroblast function and gene expression across skin, lung, bone, liver and stomach lining 4. The biology in it is genuine. It does claim hair, in a bullet list of established actions that includes "increase hair growth and thickness, enlarge hair follicle size", and it opens by noting GHK-Cu is "widely used in skin and hair products". What it never does is measure any of that. No hair count, no follicle count, no patients, and no hair study anywhere in its reference list. The affiliation on both authors is R&D Skin Biology, a company selling GHK-Cu products, and the paper carries the line "The authors declare no conflict of interest".
The human peptide GHK (glycyl-l-histidyl-l-lysine) has multiple biological actions, all of which, according to our current knowledge, appear to be health positive.Pickart L and Margolina A, International Journal of Molecular Sciences, 2018. The word "hair" does not appear in that abstract.
Do copper peptides work for hair loss on top of minoxidil?
Nobody has run that trial. No published study has tested GHK-Cu alongside minoxidil, so whether it adds anything on top is unknown in both directions. The two are aimed at different proposed bottlenecks: minoxidil opens potassium channels and lengthens the anagen (active growth) phase of the hair cycle, while GHK-Cu is aimed at the follicle's surroundings, the inflammatory environment and the collagen matrix that anchors the hair bulb 4. Plausible and untested are compatible states.
Copper peptide as the plan, or copper peptide on top of the plan
One confound is worth naming before anyone reads a result as proof. As our GHK-Cu hair page puts it: "Microneedling gets far more of it into the scalp, and independently stimulates hair, so it muddies what caused what." Needle and apply and improve, and you have learned that the combination did something.
The one independent facial trial of GHK-Cu, 13 patients after laser resurfacing, found no difference by image analysis or blinded graders; only the patients' own questionnaires favoured the copper peptide.
That result comes from skin instead of scalp, and it is the closest thing to an independent randomised test the copper peptide has anywhere on the body. The full absorption and formulation argument lives on the skin ageing page; if inflammation on the scalp is your issue instead of pattern loss, the inflammation page covers those compounds. Before and after photographs, and what they can and cannot show, are handled in our GHK-Cu before and after write-up.
One more thing this page cannot do for half its readers: every trial cited here enrolled men. Female pattern hair loss is a different diagnosis with a different work-up, 5% minoxidil is the studied option in women, and finasteride is not an option for any woman who could become pregnant. A dermatologist is not optional there.
Do collagen peptides help hair growth?
Collagen peptides are hydrolysed collagen protein, sold as a powder you drink, and they do have a hair endpoint behind them. One randomised placebo-controlled trial gave 114 women aged 20 to 50 with thigh cellulite and self-reported hair thinning 1,000 mg a day of a low-molecular-weight collagen peptide for 24 weeks, and reported a significant increase in hair shaft diameter at week 24 8. Diameter is thickness, measured in a cosmetic population; nobody has counted hairs in a marked scalp circle in diagnosed androgenetic alopecia, which is the measurement finasteride and minoxidil were held to.
The mechanism is also less settled than the powder's critics admit. Digestion breaks collagen mostly into amino acids and di- and tripeptides, and some of those fragments, notably Pro-Hyp and Gly-Pro-Hyp, are absorbed intact, measurable in blood after a dose, and active on fibroblasts in culture 8. Whether any of that reaches a hair follicle in a meaningful amount has not been tested.
Oral collagen peptides and topical GHK-Cu share the word peptide and almost nothing else: different molecules, different route, different claim, different evidence. They are routinely sold and discussed as if they were one product. Verdict for hair specifically: collagen peptides are a protein powder with one thickness result and better marketing than evidence, and if you are already eating enough protein, the hair case for them is thin.
How long before a scalp protocol shows anything: the 16 to 24 week window
Hair grows on a cycle measured in months, so a follicle has to finish its current cycle before it can respond to anything new. The trial designs reflect that. Olsen measured minoxidil at week 48 2 and Kaufman measured finasteride at one and two years 1. Neither team looked for an answer at week 8, and people who quit at week 8 to 12 because nothing has changed are stopping before the window opens.
- Weeks 1 to 8: shedding is commonIncreased shedding as follicles are pushed through their cycles is a familiar early phase on minoxidil and is described in the labelling. It reads as failure and often is not. Sudden, patchy or painful shedding is also how other scalp conditions present, so anything unusual belongs in front of a clinician instead of being waited out.
- Weeks 9 to 16: shedding settles, counts rarely moveVisible density change this early is uncommon on any protocol.
- Weeks 17 to 24: the first honest lookThis is where responders to the approved drugs start showing photographic change, usually at the temples and vertex first.
- Week 48 and year 2: where the trials measuredThe published effect sizes were read at 48 weeks and two years, so that is the horizon a fair self-assessment uses.
- Track it the way the trials didStandardised photographs at weeks 0, 12, 24 and 48, same lighting, same angle, same part. Memory is a poor hair counter in both directions.
What your DNA can and cannot say about your hair
Genetics drives pattern hair loss, and it drives it across hundreds of variants at once. Hagenaars and colleagues studied over 52,000 UK Biobank men aged 40 to 69, identified more than 250 independent genetic loci associated with severe hair loss, and built a predictor from common variants that got two things roughly right: among the men it flagged as high risk, about six in ten did have severe hair loss, and among the men it cleared, about eight in ten did not 6. That is a risk estimate, not a diagnosis.
The two markers hair genetics marketing leans on hardest are the two a consumer DNA file handles worst. The AR (androgen receptor) CAG repeat is a trinucleotide repeat length on the X chromosome, and repeat lengths are not something a SNP array (the chip consumer tests use, which reads single DNA letters one position at a time) can measure, so no report built on a 23andMe, AncestryDNA or MyHeritage file can give you a CAG repeat number. Those files do carry AR-region SNPs such as rs6152, and the AR/EDA2R locus is the strongest single signal known for pattern baldness, so AR-region risk can be read even though the marketed repeat length cannot. SRD5A1 and SRD5A2, the genes encoding the enzyme finasteride blocks, were tested directly against baldness by Ellis, Stebbing and Harrap in 58 young bald men and 114 older non-bald men, and the comparison came back empty 5.
No significant differences were found between cases and controls in allele, genotype, or haplotype frequencies for restriction fragment length polymorphisms of either gene. These findings suggest that the genes encoding the two 5alpha-reductase isoenzymes are not associated with male pattern baldness.Ellis JA, Stebbing M, Harrap SB, Journal of Investigative Dermatology, 1998
- That 1998 study had no treatment arm, so it says nothing about who responds to finasteride, and no study since has shown SRD5A2 genotype predicts finasteride response 5.
- Our 144-marker panel reads one hair-adjacent marker, COL1A1 rs1800012, which affects collagen type I transcription and is characterised mostly in bone density research. Its relevance to how firmly a hair bulb is anchored has never been tested.
- No genetic test on the market predicts response to minoxidil, finasteride, GHK-Cu or any other compound for hair. Anyone selling you one is selling a risk score with a treatment label on it. We took one of those reports apart line by line in our SelfDecode peptide report review.
- For how we decide which markers earn a place in a report, including why repeat-length markers cannot come from an array file, see our DNA decision framework.
Side effects, and the parts nobody has measured
In the Olsen trial, 5% minoxidil produced more itching and local irritation than the 2% solution, and the investigators reported no evidence of systemic effects at topical doses over 48 weeks 2. That is one trial in men, not a general safety statement. Unwanted hair growth on the face and neck is a known problem, particularly for women. Safety in pregnancy and breastfeeding is not established. Topical minoxidil is also toxic to cats and can be fatal from small incidental contact, so a treated scalp and the bottle both need to stay away from pets. Oral minoxidil, increasingly prescribed off label, carries cardiovascular monitoring requirements and belongs entirely under a physician.
The finasteride investigators described adverse effects as minimal across two years in men aged 18 to 41 1. That population and that duration do not settle the question: labelling now carries warnings covering sexual dysfunction that continued after discontinuation, and depression and suicidal ideation. Those are uncommon, they are a reason to stop and speak to a prescriber instead of pushing through, and a personal or family history of depression is worth raising before starting. Finasteride also roughly halves PSA readings, which is why prescribing clinicians record a baseline value and adjust interpretation afterwards. It is absolutely contraindicated in pregnancy because of birth defect risk, and women who are or may become pregnant should not handle crushed or broken tablets.
article · U.S. Food and Drug AdministrationCategory 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic ActThe Category 2 list, of substances FDA judged to present significant safety risks, plus the companion table of substances previously in Category 2 whose nominations were withdrawn. "GHK-Cu (for injectable routes of administration)", "BPC-157" and "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" all sit in that withdrawn table, which leaves them off both bulks lists.fda.govWhat a copper peptide scalp product costs, and what concentration the circulated protocols assume
The topical protocols that circulate online use roughly 1 to 3 mg of GHK-Cu per gram of carrier, which is 0.1% to 0.3%. Plenty of cosmetic serums sit two orders of magnitude below that, at 0.001% to 0.01%, and the label rarely tells you which you are buying. No trial establishes an effective concentration for hair at any level, so only one narrow statement holds. A trace-level product cannot reach even the concentration the circulated protocols assume, and the one label check worth doing is arithmetic: no milligram-per-gram figure on the box means you are almost certainly holding the trace version.
- Cosmetic copper peptide serums typically run from about $20 to $90 for 30 ml, and the price says nothing about the peptide concentration inside.
- Material sold as research grade is labelled for laboratory use and not for human consumption, is not manufactured sterile or to pharmaceutical purity standards, and carries no guarantee of identity, dose accuracy or freedom from contaminants. Nothing here is a suggestion to source or prepare it.
- A compounding pharmacy works to a verified concentration, but injectable GHK-Cu, BPC-157 and the thymosin beta-4 fragment are on neither FDA bulks list, so a pharmacy following federal policy has no lawful route to prepare them 7. A cosmetic label often states no concentration at all, and no regulator reviewed either for hair efficacy.
- Full compound details sit on the entity page for GHK-Cu.
Disclosure: our vendor pages carry affiliate links, and we earn a commission if you buy through them. That is why the evidence sections above rank compounds by what was measured instead of by what sells.
Stated as evidence and not as a plan for anyone: the only options with human hair counts behind them are the two FDA-approved drugs, the copper peptide has none, and a peptide layer sits on top of a question nobody has answered in either direction. Which pattern of hair loss a person has decides what is appropriate, and naming that pattern is a dermatologist's job instead of an article's. Whatever gets tried, standardised photographs at week 24 and week 48 are how the trials read results.
Wondering which of the 39 peptides have genetic markers worth reading at all, and which are marketing? Upload the raw DNA data you already have from 23andMe, AncestryDNA or MyHeritage. The report ranks all 39 by how much your own markers have been studied in relation to each compound, and it writes the limits in, including that no consumer DNA file predicts who responds to any peptide or hair drug, and that the AR CAG repeat cannot be read from a SNP array at all.
Get your DNA report- The scalp's most popular peptide rests on a two-page 1991 abstract from the company that sold it
The primary animal hair citation for GHK-Cu is Trachy et al., Annals of the New York Academy of Sciences 1991, pages 468 to 469: a conference abstract in C3H mice, authored at ProCyte Corporation, which sold the copper peptide hair product. PubMed carries no abstract text for it. The treatments it gets layered on top of, finasteride and 5% minoxidil, have hair counts from 1,553 and 393 men.
- Follicle activity is not a hair count
Every peptide hair claim measures something upstream of the endpoint you care about: a mouse follicle entering its growth phase, a dermal papilla cell dividing in a culture well, a gene expression pattern in a mechanism review. Finasteride and minoxidil were measured by counting hairs in a marked circle of scalp on human beings. The distance between those two kinds of result is where the marketing lives.
Frequently asked questions
Do copper peptides work for hair loss?
No published human trial has tested whether GHK-Cu regrows hair, alone or alongside minoxidil. The animal hair evidence is a two-page 1991 conference abstract in C3H mice from the company that sold the copper peptide hair product. The mechanism work on follicle stem cells, inflammation and the collagen matrix is genuine biology, and it contains no hair measurement. If someone uses GHK-Cu, the evidence supports treating it as an unproven layer on top of the approved drugs instead of a substitute for them, and judging results on standardised photographs. Which treatment is appropriate depends on the pattern of hair loss, which a dermatologist identifies.
Do collagen peptides help hair growth?
There are hair endpoints, and they are not hair counts in pattern hair loss. One randomised placebo-controlled trial gave 114 women aged 20 to 50 with thigh cellulite and self-reported hair thinning 1,000 mg a day of a low-molecular-weight collagen peptide for 24 weeks and reported a significant increase in hair shaft diameter at week 24 [[8]]. That is thickness in a cosmetic population, and no trial has counted hairs in a marked scalp circle in diagnosed androgenetic alopecia. Digestion breaks collagen powder mostly into amino acids and short fragments, some of which (Pro-Hyp and Gly-Pro-Hyp) are absorbed intact and measurable in blood; whether any of that reaches a hair follicle in a meaningful amount has not been tested. Oral collagen peptides are a completely different product from the topical copper peptide GHK-Cu despite the shared word.
Can GHK-Cu replace minoxidil or finasteride?
The evidence points the other way. Topical 5% minoxidil beat 2% minoxidil and placebo on non-vellus hair count over 48 weeks in 393 men, and finasteride 1 mg daily raised hair counts by 107 and 138 hairs versus placebo at one and two years in 1,553 men. GHK-Cu has no human hair count at all, and nobody has measured whether it touches DHT, the androgen that drives pattern hair loss. Swapping a compound with two-year hair counts for one with a mouse abstract inverts the evidence. Which treatment is appropriate for you depends on your pattern of hair loss, which a dermatologist identifies.
Is injecting GHK-Cu into the scalp better than a serum?
No published human trial has tested injected GHK-Cu for hair, so the higher local concentration is a theoretical advantage with no outcome data behind it. Injectable GHK-Cu was placed in Category 2 of FDA's interim bulk-substances policy and now sits in FDA's nominated-but-withdrawn table, which leaves it off the 503A and 503B bulks lists, so a compounding pharmacy has no lawful route to prepare it under section 503A [[7]]. Scalp mesotherapy also requires sterile technique in a clinic, and self-injection adds infection risk and uneven distribution for a route nobody has shown works.
Sources9
- Kaufman KD et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998;39(4 Pt 1):578-589 (1,553 men aged 18 to 41, 2 years, hair count +107 and +138 vs placebo from a baseline of 876 per 1-inch circle; adverse effects described as minimal). PMID 9777765
- Olsen EA et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47:377-385 (n=393, aged 18 to 49, 48 weeks, 45% more regrowth than 2%, increased pruritus and irritation, no evidence of systemic effects). PMID 12196747
- Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Ann N Y Acad Sci 1991;642:468-469 (two-page conference abstract, ProCyte Corporation affiliation, no abstract indexed). PMID 1809108
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci 2018;19(7):1987 (mechanism review, R&D Skin Biology affiliation; asserts increased hair growth and follicle size in a bullet list of established actions, reports no hair measurement and cites no hair study). PMID 29986520
- Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male pattern baldness and the 5alpha-reductase genes. J Invest Dermatol 1998;110:849-853 (58 bald cases aged 18 to 30, 114 non-bald controls aged 50 to 70, null result, no treatment arm). PMID 9620288
- Hagenaars SP et al. Genetic prediction of male pattern baldness. PLoS Genet 2017;13(2):e1006594 (52,000+ UK Biobank men aged 40 to 69, 250+ loci; AUC 0.78, sensitivity 0.74, specificity 0.69, PPV 59%, NPV 82%). PMID 28196072
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 of the bulk substances nominated under sections 503A or 503B). Page last updated April 2026; GHK-Cu for injectable routes, BPC-157 and thymosin beta-4 fragment (LKKTETQ, TB-500) appear in the companion table of substances previously in Category 2 whose nominations were withdrawn. Checked 14 August 2026
- Hwang S et al. Low-molecular-weight collagen peptide supplementation improves cellulite severity, skin elasticity, and hair shaft diameter: a clinical study with pharmacokinetic evaluation. J Med Food 2026;29(4):187-195 (randomised placebo-controlled, 114 women aged 20 to 50 with cellulite and self-reported hair thinning, 1,000 mg/day for 24 weeks, significant increase in hair diameter at week 24; Gly-Pro-Hyp systemic exposure roughly 54-fold higher than general collagen). PMID 41788055
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg 2006;8(4):252-259 (13 patients completed; computer analysis and blinded evaluators found no significant difference; patient questionnaire favoured GHK-Cu, P=.04). PMID 16847171
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
This page is educational and is not medical advice. Peptides are not intended to diagnose, treat, cure, or prevent any disease, and most are not FDA-approved. Talk to a qualified healthcare provider before starting anything. Availability and legal status of peptides vary by jurisdiction.
← All condition guides